Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

placebo to certolizumab pegol after 12 weeks.*  

A total of 770 patients who had previously been given certolizumab pegol, and 184 patients who had been given placebo, entered the extension study. At 28 weeks, ACR20 response rates were 59.7% (n=770) for patients taking certolizumab pegol for 28 weeks and 53.3% (n=184) for those taking it for 16 weeks following the initial placebo phase. DAS28(CRP) remission (DAS28 <2.6) was achieved in 22.9% and 21.7% (p=no significant difference) of patients, respectively, while DAS28(ESR) remission (DAS28 <2.6) was achieved in 15.2% and 11.4% (p=no significant difference) of completers, respectively.

Treatment with certolizumab pegol was associated with rapid and consistent efficacy and sustained improvements in disease activity and physical function up to Week 28 in a diverse group of patients with RA closely resembling those seen in routine clinical practice. Rapid efficacy was also seen across patients receiving concomitant DMARDs at baseline, regardless of the number or type of concomitant DMARDs.

In the placebo controlled portion of the trial, the most common serious infections were lower respiratory tract and lung infections. The most common adverse events were infections and infestations, musculoskeletal and connective tissue disorders, and nervous system disorders. Incidence of adverse in the OLE phase was 305.8 events per 100 patient years in patients randomized to certolizumab pegol in the double blind period compared to 406.2 in patients randomised to placebo and switched to certolizumab pegol in the OLE. Incidence of serious adverse events per 100 patient years was 14.7 vs 16.3, respectively.

* Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

For further Information:
Scott Fleming, Global Communications Manager – Immunology
T +44 770.277.737
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DIEGO , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... and development of drugs targeting unmet needs in oncology, autoimmune ... Baird 2014 Health Care Conference to be held at The ... on September 3-4, 2014. Alan ... Company and its lead drug candidate, quizartinib, at 1:10 p.m. ...
(Date:8/27/2014)... 27, 2014  After the February 2014 launch of ... solution for medical practices and management companies, Prime ... new software. "The feedback has been great," ... "The sheer number of demos and new sign-ups is ... for these types of software features." ...
(Date:8/27/2014)... 27, 2014  Zimmer Holdings, Inc. (NYSE and SIX: ... it will be participating in the Morgan Stanley 2014 ... New York, New York , on Tuesday, ... CEO of Zimmer, will be presenting at 9:10 a.m. ... of Biomet, will join Mr. Dvorak for the Q&A ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
... 9, 2012 Young Innovations, Inc. (NASDAQ – YDNT) ... quarterly dividend of $0.04 per share, payable June 15, ... 2012. Young Innovations develops, manufactures and markets ... assistants and consumers. The Company,s consumables product offering includes ...
... for WAISMANN METHOD® rapid opiate detox treatment ... support for National Fibromyalgia Awareness Day, taking place on ... are being prescribed opiate painkillers to address their chronic ... prescription painkiller use is also surging nationwide.  ...
Cached Medicine Technology:Young Innovations, Inc. Board Of Directors Declares Quarterly Dividend 2WAISMANN METHOD® Medical Director Voices Support for Fibromyalgia Awareness Day 2
(Date:8/27/2014)... Lee Antimicrobial Solutions LLC (“LAMS”), the ... and a Leader in Environmental Disinfection Device Design, ... device developed for home use available for the ... DHP Technology, a revolutionary means to disinfect your ... bacteria, viruses, microbes and offensive odors. A technology ...
(Date:8/27/2014)... York (PRWEB) August 27, 2014 Power ... in U.S. courts on behalf of women who allegedly ... morcellation, Bernstein Liebhard LLP reports. According to court documents, ... August 18th in the U.S. District Court, Northern District ... who claims the use of a power morcellator manufactured ...
(Date:8/27/2014)... 2014 Picture, if you will, a detective ... but more of a Mr. Inside, a Doc Blanchard type, ... personalities and world view. This Mr. Inside was an internationally ... Austin, and Mr. Outside was an Austin Police Department lieutenant. ... girlfriend, and a gaggle of teenagers embarked on a mission ...
(Date:8/27/2014)... When Jagger was 20 years old and at ... that he credits as one of the most memorable phone ... she could set him up with a summer job; one ... that job, and he has now spent the past 22 ... he also worked in school boards, employment programs and youth ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The newest ... PA on Monday, September 8, 2014. This new 15,000 ... that features three primary care practices and walk-in laboratory ... is a very exciting endeavor for Abington Health as ... and CEO, Abington Health. “Establishing a location in Lower ...
Breaking Medicine News(10 mins):Health News:A New York Based Company Announces The Release Of An Advanced, Environmentally Friendly Disinfection Technology For In-Home Use 2Health News:A New York Based Company Announces The Release Of An Advanced, Environmentally Friendly Disinfection Technology For In-Home Use 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:UW Rankin Self-Publishes Debut Novel, Sublimity: Perchance to Dream, A Speculative Science Mystery 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 4Health News:Abington Health Opens New Health Center in Lower Gwynedd 2
... WASHINGTON, DC -- A study in the December issue of ... as to why death rates for less educated middle aged ... despite increased awareness and treatments aimed at reducing health disparities. ... with low education levelsthat is high school or lessare twice ...
... HealthDay Reporter , WEDNESDAY, Dec. 14 (HealthDay News) -- Every ... rape, physical violence, or stalking by an intimate partner, according ... to data from the U.S. Centers for Disease Control and ... of partner violence each year, with by far the biggest ...
... 14 (HealthDay News) -- ,Headache affects 50 percent of HIV/AIDS ... are severe, a new study says. About 27.5 percent ... migraine," a rare condition in which a person has migraine ... days a month. This condition occurs in only 2 percent ...
... will have been diagnosed with locally-advanced pancreatic cancer in ... treatment option for these patients whose tumor has grown ... the past 20 years, numerous treatment regimens have been ... by chemoradiation being the current standard approach. However, the ...
... countries rely on traditional medicine as an accessible and ... scientific data has not existed to evaluate the potential ... the William L. Brown Center of the Missouri Botanical ... shrimp to determine the toxicity of 341 Northern Peruvian ...
... HealthDay Reporter , WEDNESDAY, Dec. 14 (HealthDay News) ... from sensing or reacting to anything happening to their ... recognizing a person sitting to that side -- may recover ... brain, Italian researchers report. This inability to process and ...
Cached Medicine News:Health News:Study takes aim at education-based death rate disparities 2Health News:Millions of Americans Are Victims of Sexual Violence: CDC 2Health News:Millions of Americans Are Victims of Sexual Violence: CDC 3Health News:Headaches May Plague Many With HIV/AIDS 2Health News:RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer 2Health News:Missouri Botanical Garden scientists examine toxicity of medicinal plants in Peru 2Health News:Missouri Botanical Garden scientists examine toxicity of medicinal plants in Peru 3Health News:Magnetic Brain Stimulation Might Help Some Stroke Patients 2Health News:Magnetic Brain Stimulation Might Help Some Stroke Patients 3
... is the First and Only ... the powerful technology of RESTORE with ... to create the unrivaled RESTOREPRIME. The ... and coverage for managing patients with ...
The S4 Spinal System has quickly gained a reputation for being the next generation in pedicle screw systems because of its exceptionally small size and high biomechanical strength....
NIVEA body Good-bye Cellulite Gel-Cream visibly reduces the appearance of cellulite....
... Atlas II HF systems are intended to ... for automated treatment of life-threatening ventricular arrhythmias. ... Atlas II HF systems are also intended:, ... symptoms of moderate to severe heart failure ...
Medicine Products: